ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients

D. Rodríguez-Espinosa, E. Montagud-Marrahi, J. Cacho, C. Arana, N. Taurizano, E. Hermida, J. Del Risco, J. Casals, A. Rosario, E. Cuadrado, N. Rodríguez, I. Revuelta, B. Bayès, P. Ventura-Aguiar, F. Cofan, E. Poch, F. Oppenheimer, M. Vera, L. Rodas, F. Maduell, F. Diekmann, A. Cases, J. Broseta, D. Cucchiari

Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain

Meeting: 2022 American Transplant Congress

Abstract number: 1641

Keywords: COVID-19, Efficacy, Kidney transplantation, Vaccination

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) IV

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and cellular response after mRNA vaccination in this population compared to hemodialysis patients. However, there is currently no information on real-life clinical protection (deaths and hospitalizations), a gap that this study aims to fill.

*Methods: Observational prospective study. A total population of 1336 KTR and hemodialysis patients from three dialysis units affiliated to Hospital Clínic of Barcelona, Spain, vaccinated with two doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 mRNA vaccines. The outcomes measured were SARS-CoV-2 infection diagnosed by a positive RT-PCR fourteen days after the second vaccine dose, hospital admissions derived from infection, and a severe COVID-19 composite outcome, defined as either ICU admission, invasive and non-invasive mechanical ventilation, or death.

*Results: Six per cent (18/302) of patients on hemodialysis were infected, of whom four required hospital admission (1.3%), only one (0.3%) had severe COVID-19, and none of them died. In contrast, 4.3% (44/1034) of KTR were infected, and presented more hospital admissions (26 patients, 2.5%), severe COVID-19 (11 patients, 1.1%) or death (4 patients, 0.4%). There were no correlations on the multivariate analysis between measured outcomes and baseline characteristics nor immunosuppressive treatment.

*Conclusions: The study highlights the need for further booster doses in KTR. In contrast, the hemodialysis population appears to have an adequate clinical response to vaccination, at least up to four months from its administration.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Rodríguez-Espinosa D, Montagud-Marrahi E, Cacho J, Arana C, Taurizano N, Hermida E, Risco JDel, Casals J, Rosario A, Cuadrado E, Rodríguez N, Revuelta I, Bayès B, Ventura-Aguiar P, Cofan F, Poch E, Oppenheimer F, Vera M, Rodas L, Maduell F, Diekmann F, Cases A, Broseta J, Cucchiari D. Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/real-life-prevention-of-breakthrough-sars-cov-2-infections-by-mrna-vaccines-in-kidney-transplant-recipients-vs-hemodialysis-patients/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences